文献速递性腺与生殖内分泌垂体与肾上腺疾病

实验性与治疗性睾丸抑制中的血清胰岛素样因子3、睾酮与促黄体生成素

Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究纳入3个队列,分别观察健康年轻男性接受雄激素注射、跨性别女孩接受GnRH激动剂、前列腺癌患者接受手术或药物去势前后血清INSL3、睾酮与LH的变化。结果显示,实验性和治疗性睾丸抑制期间三种激素均下降,实验性抑制解除后回升至基线。作者认为INSL3可反映睾丸抑制和Leydig细胞功能,或可补充睾酮作为Leydig细胞标志物。

要点

  • 在健康年轻男性接受雄激素注射的实验性睾丸抑制中,INSL3、睾酮与LH均下降,抑制解除后回升至基线。
  • 在跨性别女孩和前列腺癌患者的治疗性睾丸抑制中,INSL3、睾酮与LH均下降。
  • 作者认为INSL3可反映Leydig细胞功能,或可补充睾酮作为睾丸抑制的标志物。

核心结论

  • INSL3类似睾酮,是睾丸抑制的敏感标志物,可反映Leydig细胞功能,包括暴露于外源性睾酮期间。
  • 作者认为血清INSL3检测或可补充睾酮作为男性生殖障碍中的Leydig细胞标志物,用于治疗性睾丸抑制及非法雄激素使用监测。

研究设计与样本

  • 研究纳入3个不同队列,比较睾丸抑制前后的血清样本:6名健康年轻男性接受雄激素(Sustanon)治疗;10名跨性别女孩(出生时指定性别为男性)接受每3个月一次GnRH激动剂(亮丙瑞林)注射;55名前列腺癌患者随机接受手术去势(双侧包膜下睾丸切除术)或GnRH激动剂(曲普瑞林)治疗。
  • 血清INSL3与睾酮采用经验证的液相色谱-串联质谱法在储存血清样本中定量,LH采用超灵敏免疫分析法测定。

主要发现

  • 在健康年轻男性接受Sustanon注射的实验性睾丸抑制期间,INSL3、睾酮与LH的循环浓度均下降,抑制解除后回升至基线水平。
  • 在跨性别女孩和前列腺癌患者的治疗性下丘脑-垂体-睾丸抑制期间,三种激素均下降。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum insulin-like factor 3 (INSL3) is a Leydig cell biomarker, but little is known about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular suppression. AIM: To study the concomitant changes in serum concentrations of INSL3, testosterone, and LH during experimental and therapeutic testicular suppression. METHODS: We included serum samples from 3 different cohorts comprising subjects before and after testicular suppression: (1) 6 healthy young men who were treated with androgens (Sustanon, Aspen Pharma, Dublin, Ireland); 2) 10 transgender girls (male sex assigned at birth) who were treated with 3-monthly GnRH agonist injections (Leuprorelinacetat, Abacus Medicine, Copenhagen, Denmark); and (3) 55 patients with prostate cancer who were randomized to surgical castration (bilateral subcapsular orchiectomy) or treatment with GnRH agonist (Triptorelin, Ipsen Pharma, Kista, Sweden). Serum INSL3 and testosterone concentrations were quantified in stored serum samples using validated liquid chromatography-tandem mass spectrometry methodologies, and LH was measured by an ultrasensitive immunoassay. RESULTS: The circulating concentrations of INSL3, testosterone, and LH decreased during experimental testicular suppression in healthy young men by Sustanon injections and subsequently returned to baseline levels after release of suppression. All 3 hormones decreased during therapeutic hormonal hypothalamus-pituitary-testicular suppression in transgender girls and in patients with prostate cancer. CONCLUSION: INSL3 resembles testosterone as a sensitive marker of testicular suppression and reflects Leydig cell function, also during exposure to exogenous testosterone. Serum INSL3 measurements may complement testosterone as a Leydig cell marker in male reproductive disorders, during therapeutic testicular suppression as well as in surveillance of illicit use of androgens.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Albrethsen J, Østergren PB, Norup PB, et al. Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. J Clin Endocrinol Metab. 2023. PMID: 37235781. doi:10.1210/clinem/dgad291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。